Financial reports
10-Q
2024 Q2
Quarterly report
22 Mar 24
NT 10-Q
Notice of late quarterly filing
18 Mar 24
10-Q
2024 Q1
Quarterly report
15 Dec 23
10-K/A
2023 FY
Annual report (amended)
28 Nov 23
10-K
2023 FY
Annual report
30 Oct 23
10-Q
2023 Q3
Quarterly report
14 Jun 23
10-Q
2023 Q2
Quarterly report
17 Mar 23
10-Q
2023 Q1
Quarterly report
14 Dec 22
10-K
2022 FY
Annual report
31 Oct 22
10-Q
2022 Q3
Quarterly report
14 Jun 22
Current reports
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
29 Dec 23
8-K
Regulation FD Disclosure
13 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
7 Dec 23
8-K
Entry into a Material Definitive Agreement
2 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
5 Oct 23
8-K
Entry into a Material Definitive Agreement
18 Aug 23
8-K
Entry into a Material Definitive Agreement
7 Jul 23
8-K
Regulation FD Disclosure
28 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
5 Jan 24
S-8
Registration of securities for employees
5 Jan 24
8-A12G
Registration of securities
5 Jan 24
424B3
Prospectus supplement
9 Aug 22
S-1
IPO registration
29 Jul 22
D
$5M in equity / options, sold $1.42M, 26 investors
13 Jun 22
RW
Registration withdrawal request
21 Apr 21
S-3
Shelf registration
17 Mar 21
D
$2.5M in equity / options
9 Mar 21
424B3
Prospectus supplement
8 Dec 20
Proxies
Other
EFFECT
Notice of effectiveness
9 Aug 22
CORRESP
Correspondence with SEC
4 Aug 22
UPLOAD
Letter from SEC
3 Aug 22
EFFECT
Notice of effectiveness
7 Dec 20
CORRESP
Correspondence with SEC
30 Nov 20
UPLOAD
Letter from SEC
27 Nov 20
EFFECT
Notice of effectiveness
30 Jul 15
CORRESP
Correspondence with SEC
28 Jul 15
CORRESP
Correspondence with SEC
29 Apr 15
UPLOAD
Letter from SEC
24 Mar 15